Forum Financial Management LP Purchases 172 Shares of Jazz Pharmaceuticals PLC $JAZZ

Forum Financial Management LP increased its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 7.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,400 shares of the specialty pharmaceutical company’s stock after buying an additional 172 shares during the quarter. Forum Financial Management LP’s holdings in Jazz Pharmaceuticals were worth $255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in Jazz Pharmaceuticals by 63.7% in the 1st quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company’s stock valued at $126,000 after acquiring an additional 395 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Jazz Pharmaceuticals by 5.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,334 shares of the specialty pharmaceutical company’s stock valued at $538,000 after acquiring an additional 232 shares during the period. Spire Wealth Management increased its position in Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 161 shares during the period. KBC Group NV increased its position in Jazz Pharmaceuticals by 3.2% in the 1st quarter. KBC Group NV now owns 243,938 shares of the specialty pharmaceutical company’s stock valued at $30,285,000 after acquiring an additional 7,620 shares during the period. Finally, Kendall Capital Management grew its position in shares of Jazz Pharmaceuticals by 1.2% in the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company’s stock valued at $989,000 after buying an additional 95 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $139.33 on Tuesday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The stock has a 50-day moving average of $130.88 and a 200-day moving average of $117.25. The company has a market cap of $8.45 billion, a PE ratio of -20.70, a P/E/G ratio of 8.23 and a beta of 0.28. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Truist Financial raised their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Royal Bank Of Canada raised their price target on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price target on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company set a $170.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, October 22nd. Fourteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $179.33.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 3,500 shares of the company’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $140.00, for a total value of $490,000.00. Following the sale, the director owned 408,826 shares in the company, valued at $57,235,640. This represents a 0.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders sold 11,500 shares of company stock valued at $1,525,280. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.